Tecentriq, chemo combo shows bladder cancer promise
Tecentriq was the first cancer immunotherapy approved in bladder cancer.
Read More
Tag: PFS
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read More
EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
New US approval for Clovis’ Rubraca
Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Read More
AZ announces results delay for key lung cancer trial
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
Read More
Novartis’ Kisqali shows PFS benefit in premenopausal breast cancer
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Read More
Breakthrough status for AZ’ lung cancer drug Imfinzi
US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC).
Read More
US OKs first-line use of Novartis’ Zykadia in lung cancer
US regulators have green-lighted the use of Novartis Zykadia as a first-line treatment option for some patients with non-small cell lung cancer.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
